8-KOther EventsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Corporate Update (Nov 22, 2022)

Filed November 22, 2022For Securities:ONCBEIGF

Summary

BeOne Medicines Ltd. (ONC), through its affiliate BeiGene, Ltd., announced significant developments concerning its drug BRUKINSA® (zanubrutinib). Most notably, the European Commission has granted approval for BRUKINSA® in the treatment of adult patients with chronic lymphocytic leukemia (CLL), marking a key market expansion for the drug. This approval covers both treatment-naïve and relapsed/refractory patient populations, increasing the addressable market within Europe. Furthermore, BeiGene will present the final progression-free survival (PFS) results from the pivotal ALPINE Phase 3 trial at the upcoming American Society of Hematology (ASH) Annual Meeting. This trial directly compares BRUKINSA® against IMBRUVICA® (ibrutinib) in patients with relapsed/refractory CLL or small lymphocytic leukemia (SLL). The presentation of final PFS data is a critical event for investors, as it is expected to demonstrate superior efficacy for BRUKINSA®, potentially reinforcing its competitive position and future market share.

Key Highlights

  • 1European Commission approval granted for BRUKINSA® (zanubrutinib) in adult patients with Chronic Lymphocytic Leukemia (CLL).
  • 2Approval covers both treatment-naïve and relapsed/refractory CLL patient populations in Europe.
  • 3BeiGene to present final Progression-Free Survival (PFS) results from the ALPINE Phase 3 trial at ASH 2022.
  • 4The ALPINE trial is a head-to-head comparison of BRUKINSA® against IMBRUVICA® (ibrutinib) in relapsed/refractory CLL/SLL.
  • 5Presentation at ASH 2022 is a late-breaking oral presentation, indicating significant clinical significance.
  • 6Expected outcome from ALPINE trial presentation is a demonstration of superior PFS for BRUKINSA® over IMBRUVICA®.

Frequently Asked Questions

The European Commission's approval for BRUKINSA® (zanubrutinib) in adult CLL patients is a major milestone, expanding its commercial reach into a significant European market. This approval for both treatment-naïve and relapsed/refractory settings broadens the potential patient base and revenue opportunities for the drug.

The ALPINE trial is a Phase 3 clinical study comparing BRUKINSA® head-to-head against IMBRUVICA® (ibrutinib), a well-established drug, in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic leukemia. The presentation of the final progression-free survival (PFS) results at the ASH Annual Meeting is crucial as it is expected to demonstrate BRUKINSA®'s superior efficacy, potentially strengthening its market position and encouraging broader physician and patient adoption.

The final progression-free survival (PFS) results from the ALPINE trial will be presented as a late-breaking oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans on Tuesday, December 13, 2022, at 10:15 am CST in Hall E.

This filing highlights BeOne Medicines' (through its affiliate BeiGene) strategic focus on advancing and expanding the market presence of BRUKINSA® in key hematological oncology indications. The European approval and the presentation of superior efficacy data in a competitive landscape suggest a strong commercial and clinical development strategy aimed at capturing significant market share in CLL and potentially other B-cell malignancies.